FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384695511> ?p ?o ?g. }

• W4384695511 abstract "The management of recurrent WHO grades II-III (rGII-III) glioma is not well established. This study describes the clinical outcomes in patients who received bevacizumab as rescue treatment.In this retrospective study, the main inclusion criteria were as follows: adult patients with histologicaly proved rGII-III glioma according 2016 WHO classification treated with bevacizumab from 2011 to 2019, T1 contrast enhancement on MRI. Efficacy was assessed using the high-grade glioma 2017 Response Assessment in Neuro-Oncology criteria. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.Eighty-one patients were included (M/F ratio: 1.7, median age at diagnosis: 38 years) among whom 46 (56.8%) had an initial diagnosis of grade II glioma. Previous treatments included at least one surgical intervention, radiotherapy (98.8%), and ≥ 2 chemotherapy lines (64.2%). After bevacizumab initiation, partial response, stable disease, and progressive disease were observed in 27.2%, 22.2%, and 50.6% of patients. The median PFS and OS were 4.9 months (95% confidence interval [CI] 3.7-6.1) and 7.6 months (95% CI 5.5-9.9). Bevacizumab severe toxicity occurred in 12.3%. Twenty-four (29.6%) patients discontinued bevacizumab without radiological progression. Oligodendroglioma and age ≥ 38 years at diagnosis were more frequent in this subgroup (odds ratio = 0.24, 95% CI 0.07-0.84, p = 0.023 and 0.36, 95% CI 0.13-0.99, p = 0.042). Ten of these 24 patients were alive at 12 months and two patients at 8 years after bevacizumab initiation, without any subsequent treatment.Bevacizumab can be an option for heavily pretreated patients with rGII-III glioma with contrast enhancement. In our study, bevacizumab displayed prolonged activity in a subgroup of patients." @default.
• W4384695511 created "2023-07-20" @default.
• W4384695511 creator A5005504247 @default.
• W4384695511 creator A5020440025 @default.
• W4384695511 creator A5022285372 @default.
• W4384695511 creator A5032457110 @default.
• W4384695511 creator A5058944662 @default.
• W4384695511 creator A5080559188 @default.
• W4384695511 creator A5085603280 @default.
• W4384695511 creator A5086083902 @default.
• W4384695511 date "2023-07-18" @default.
• W4384695511 modified "2023-10-14" @default.
• W4384695511 title "Bevacizumab in recurrent WHO grades II–III glioma" @default.
• W4384695511 cites W1757089901 @default.
• W4384695511 cites W1851035350 @default.
• W4384695511 cites W1862835589 @default.
• W4384695511 cites W1969656908 @default.
• W4384695511 cites W1973753581 @default.
• W4384695511 cites W1978041336 @default.
• W4384695511 cites W1989754795 @default.
• W4384695511 cites W2020304503 @default.
• W4384695511 cites W2021791122 @default.
• W4384695511 cites W2025063591 @default.
• W4384695511 cites W2036044314 @default.
• W4384695511 cites W2048796627 @default.
• W4384695511 cites W2050999161 @default.
• W4384695511 cites W2056342586 @default.
• W4384695511 cites W2093783077 @default.
• W4384695511 cites W2129442496 @default.
• W4384695511 cites W2130139391 @default.
• W4384695511 cites W2132697290 @default.
• W4384695511 cites W2142630775 @default.
• W4384695511 cites W2144487043 @default.
• W4384695511 cites W2146113976 @default.
• W4384695511 cites W2150093581 @default.
• W4384695511 cites W2156330848 @default.
• W4384695511 cites W2158106887 @default.
• W4384695511 cites W2158501128 @default.
• W4384695511 cites W2163466967 @default.
• W4384695511 cites W2163501248 @default.
• W4384695511 cites W2170367762 @default.
• W4384695511 cites W2171074831 @default.
• W4384695511 cites W2366536035 @default.
• W4384695511 cites W2604815509 @default.
• W4384695511 cites W2610403529 @default.
• W4384695511 cites W2651525809 @default.
• W4384695511 cites W2789731973 @default.
• W4384695511 cites W2886993778 @default.
• W4384695511 cites W2900482723 @default.
• W4384695511 cites W2901864445 @default.
• W4384695511 cites W2918622468 @default.
• W4384695511 cites W2956623165 @default.
• W4384695511 cites W2988596572 @default.
• W4384695511 cites W3017270631 @default.
• W4384695511 cites W3110787789 @default.
• W4384695511 cites W3120935559 @default.
• W4384695511 cites W3140904496 @default.
• W4384695511 cites W3169383648 @default.
• W4384695511 cites W3173064115 @default.
• W4384695511 cites W3174246647 @default.
• W4384695511 cites W3205343391 @default.
• W4384695511 cites W4206971720 @default.
• W4384695511 cites W4251989766 @default.
• W4384695511 cites W4301595791 @default.
• W4384695511 cites W4313544674 @default.
• W4384695511 doi "https://doi.org/10.3389/fonc.2023.1212714" @default.
• W4384695511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37534252" @default.
• W4384695511 hasPublicationYear "2023" @default.
• W4384695511 type Work @default.
• W4384695511 citedByCount "1" @default.
• W4384695511 countsByYear W43846955112023 @default.
• W4384695511 crossrefType "journal-article" @default.
• W4384695511 hasAuthorship W4384695511A5005504247 @default.
• W4384695511 hasAuthorship W4384695511A5020440025 @default.
• W4384695511 hasAuthorship W4384695511A5022285372 @default.
• W4384695511 hasAuthorship W4384695511A5032457110 @default.
• W4384695511 hasAuthorship W4384695511A5058944662 @default.
• W4384695511 hasAuthorship W4384695511A5080559188 @default.
• W4384695511 hasAuthorship W4384695511A5085603280 @default.
• W4384695511 hasAuthorship W4384695511A5086083902 @default.
• W4384695511 hasBestOaLocation W43846955111 @default.
• W4384695511 hasConcept C126322002 @default.
• W4384695511 hasConcept C141071460 @default.
• W4384695511 hasConcept C143998085 @default.
• W4384695511 hasConcept C156957248 @default.
• W4384695511 hasConcept C167135981 @default.
• W4384695511 hasConcept C2776694085 @default.
• W4384695511 hasConcept C2777802072 @default.
• W4384695511 hasConcept C2777931997 @default.
• W4384695511 hasConcept C2778227246 @default.
• W4384695511 hasConcept C2778822529 @default.
• W4384695511 hasConcept C2778880634 @default.
• W4384695511 hasConcept C2780739268 @default.
• W4384695511 hasConcept C44249647 @default.
• W4384695511 hasConcept C502942594 @default.
• W4384695511 hasConcept C509974204 @default.
• W4384695511 hasConcept C71924100 @default.
• W4384695511 hasConcept C90924648 @default.
• W4384695511 hasConceptScore W4384695511C126322002 @default.
• W4384695511 hasConceptScore W4384695511C141071460 @default.

• next